WO2017164411A1 - PROCÉDÉ ANTICANCÉREUX OU MATÉRIAU ANTICANCÉREUX UTILISANT UN MÉLANGE DE FUCOIDAN ET DE VINAIGRE MOROMI<i /> - Google Patents

PROCÉDÉ ANTICANCÉREUX OU MATÉRIAU ANTICANCÉREUX UTILISANT UN MÉLANGE DE FUCOIDAN ET DE VINAIGRE MOROMI<i /> Download PDF

Info

Publication number
WO2017164411A1
WO2017164411A1 PCT/JP2017/012202 JP2017012202W WO2017164411A1 WO 2017164411 A1 WO2017164411 A1 WO 2017164411A1 JP 2017012202 W JP2017012202 W JP 2017012202W WO 2017164411 A1 WO2017164411 A1 WO 2017164411A1
Authority
WO
WIPO (PCT)
Prior art keywords
fucoidan
moromi vinegar
moromi
vinegar
growth rate
Prior art date
Application number
PCT/JP2017/012202
Other languages
English (en)
Japanese (ja)
Inventor
哲 渡嘉敷
Original Assignee
株式会社クレイ沖縄
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社クレイ沖縄 filed Critical 株式会社クレイ沖縄
Priority to JP2018507462A priority Critical patent/JP6913266B2/ja
Publication of WO2017164411A1 publication Critical patent/WO2017164411A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A23L33/145—Extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • the present invention relates to an invention in which fucoidan such as acetyl fucoidan can be reduced by using a method or substance for mixing fucoidan and moromi vinegar, and cheap moromi vinegar can be substituted.
  • fucoidan such as acetyl fucoidan
  • mozuku is the main component, and moromi vinegar and brown sugar and appropriate drinking water are added to this as well.
  • a health food drink which is prepared by mixing and heating with stirring, and simultaneously applying an AC voltage for a certain period of time with an electrostatic induction device to refine the molecules of the above solution by electrostatic induction and then sterilizing. Is known.
  • mozuku extract that is, fucoidan
  • an electromagnetic alternating magnetic field is simultaneously applied to moromi vinegar and mozuku, and electrons, atoms
  • fucoidan has a molecular weight that is easily absorbed by the body through the action at the molecular level.
  • acetylfucoidan is considered promising as a pharmaceutical composition for oral administration for treating malignant tumors that develop in the digestive tract.
  • acetyl fucoidan is very expensive, it is difficult to put it to practical use for economic reasons.
  • the technical problem of the present invention has been focused on such problems, and has found that the proliferation rate of tumor cells can be further suppressed by mixing and administering inexpensive moromi vinegar.
  • the present inventors unexpectedly compared the solution added with only acetylfucoidan or moromi vinegar and the solution added with the mixture of both in comparison with the antitumor activity of the mixture added alone. It was found that the rate of decrease was high. And further examination was repeated and it came to complete this invention.
  • a pharmaceutical composition for tumor treatment containing fucoidan and moromi vinegar containing fucoidan and moromi vinegar.
  • a pharmaceutical composition that suppresses the growth rate of tumor cells containing fucoidan and moromi vinegar containing fucoidan and moromi vinegar.
  • the moromi vinegar is moromi vinegar stock solution and / or deodorized moromi vinegar and / or moromi vinegar powder and / or deodorized moromi vinegar powder, (1) or (2) A pharmaceutical composition according to 1.
  • a tumor cell growth rate suppressor characterized by suppressing the growth rate of tumor cells with a substance obtained by mixing fucoidan separated from seaweed and moromi vinegar.
  • the moromi vinegar content is 3% to 95%, and the fucoidan is derived from seaweeds such as mozuku, wakame, mekabu, kombu, hijiki, akamoku, hondaidae, It is a method for suppressing the growth rate of tumor cells described in 7).
  • the amount of the moromi vinegar is 3% to 95%, and the fucoidan is derived from seaweed such as mozuku, wakame, mekabu, kombu, hijiki, akamoku, (8) It is the described tumor cell growth rate inhibitor.
  • the moromi vinegar is moromi vinegar stock solution and / or deodorized moromi vinegar and / or moromi vinegar powder and / or deodorized moromi vinegar powder, (7) or (9) This is a method for suppressing the growth rate of tumor cells.
  • the moromi vinegar is moromi vinegar stock solution and / or deodorized moromi vinegar and / or moromi vinegar powder and / or deodorized moromi vinegar powder, described in (8) or (10) It is a substance that suppresses the growth rate of tumor cells.
  • the pharmaceutical composition containing fucoidan and moromi vinegar according to the present invention ((1) to (6) has an effect of suppressing the growth rate of tumor cells, and can be replaced by cheap moromi vinegar by reducing the amount of fucoidan used. Since various types of fucoidan are sufficient instead of acetylfucoidan, various seaweeds can be used, especially when acetylfucoidan separated from Okinawa mozuku and moromi vinegar are mixed together to reduce expensive acetylfucoidan and reduce moromi vinegar. In addition, fucoidan and moromi vinegar have no toxicity, so there are no side effects like conventional chemotherapeutic agents, reducing the burden of side effects on patients.
  • the result of the experiment is that the amount of fucoidan used can be reduced and cheap moromi vinegar can be substituted found. Since various types of fucoidan are sufficient instead of acetyl fucoidan, various seaweeds can be used. In particular, when acetyl fucoidan separated from Okinawa mozuku and moromi vinegar are mixed, there is an effect that expensive acetyl fucoidan can be reduced and cheap moromi vinegar can be substituted.
  • the moromi vinegar content is 3% to 95%
  • the fucoidan is derived from seaweeds such as mozuku, wakame, mekabu, kombu, hijiki, akamoku, hondawali, etc. Vinegar is widely used, and fucoidan can be collected from seaweeds other than Okinawa mozuku.
  • the blended amount of moromi vinegar is 3% to 95%
  • the fucoidan is derived from seaweed such as mozuku, wakame, mekabu, kombu, hijiki, akamoku. It is wide and fucoidan can be collected and used from seaweeds other than Okinawa mozuku.
  • the moromi vinegar is moromi vinegar stock solution and / or deodorized moromi vinegar and / or moromi vinegar powder and / or deodorized moromi vinegar powder and / or moromi vinegar,
  • the range of adoption is large and various raw materials can be adopted.
  • the moromi vinegar is moromi vinegar stock solution and / or deodorized moromi vinegar and / or moromi vinegar powder and / or deodorized moromi vinegar powder and / or moromi vinegar,
  • the range of adoption is large and various raw materials can be adopted.
  • FIG. 4 is a flowchart illustrating a mixing method according to the present invention.
  • Fucoidan (English name: fucoidan) is a kind of sulfated polysaccharide. It is a dietary fiber that is abundant in mucilage of brown algae such as kombu, wakame (including mekabu which is partly), and mozuku. L-fucose (polysaccharide) is a compound in which dozens to hundreds of thousands are linked by ⁇ 1-2 and ⁇ 1-4 bonds, and the average molecular weight is about 200,000. It is classified into U-fucoidan containing glucuronic acid, F-fucoidan consisting only of sulfated fucose, and G-fucoidan containing galactose. Fucoidan is a generic name, and a portion of moromi vinegar stock powder is acetyl fucoidan. In the present invention, fucoidan powder purchased from Kinshu Bio Co., Ltd. was used.
  • Moromi vinegar is a liquid obtained by compression-filtering moromi koji produced in the manufacturing process of “Awamori”, a distilled liquor from Okinawa (Ryukyu Islands). Although it is called moromi vinegar, it contains almost no acetic acid and is a soft drink rich in amino acids and citric acid. In the present invention, a powdered moromi vinegar stock solution purchased from Niisato Sake Brewery was used.
  • the pharmaceutical composition of the present invention can be produced by mixing a concentrated powder or an undiluted solution produced from a stock solution of moromi vinegar with fucoidan powder.
  • the ratio of fucoidan and moromi vinegar can be adjusted to maximize the effect of suppressing the growth rate of tumor cells.
  • the ratio of fucoidan and moromi vinegar is 1 to 9 parts by weight, preferably 1 to 3 parts by weight, and more preferably 1 part by weight with respect to 1 part by weight of fucoidan.
  • the pharmaceutical composition of the present invention is preferably a pharmaceutical composition for oral administration.
  • the pharmaceutical composition for oral administration of the present invention may be a powder, a kneaded product, a tablet liquid or a tablet, preferably a powder, a kneaded product or a tablet.
  • the solid preparation of the present invention is preferably further encapsulated or subjected to a coating treatment on the surface. Encapsulated preparations and coating preparations can be produced using known methods.
  • the yield of acetylfucoidan is as follows.
  • the yield of acetyl fucoidan isolated from Okinawa mozuku is shown in Table 1. 2.3% crude polysaccharide was obtained from wet algal cells. When this crude polysaccharide was purified, a purified polysaccharide was obtained in a yield of 2.0%. These numbers were higher than the previous results.
  • Okinawa Mozuku contains only a small amount of alginic acid (1/10), and most of the macromolecules contained in algal cells can be called acetylfucoidan.
  • acetyl fucoidan The yield of acetyl fucoidan is shown in Table 1.
  • Table 2 shows the results of analyzing the total sugar, uronic acid and sulfuric acid contents of acetyl fucoidan by the phenol sulfuric acid, carbazole sulfuric acid and gelatin suspension methods.
  • the total sugar, D-glucuronic acid and sulfuric acid contents of this polysaccharide were 66.9%, 14.1% and 15.8%, respectively.
  • the components of acetyl fucoidan are as follows.
  • Table 2 shows the chemical structure of acetylfucoidan.
  • Acetylfucoidan is hydrolyzed with 2.0 M sulfuric acid (100 ° C, 2 hours), neutralized with barium carbonate, concentrated, and separated and identified by high-performance liquid chromatograph (DX500: Dionex). went. L-fucose and D-xylose were identified from the liquid chromatogram. It can be seen that most are polysaccharides composed of L-fucose.
  • Table 3 shows the growth inhibitory effect of acetylfucoidan on U937 cells.
  • the measured value of the culture solution of U937 cells to which only distilled water was added was defined as 100 (control), and the percentage relative thereto was displayed.
  • Preliminary experiments on the amount of addition were performed, and this experiment was performed under the following conditions (three types).
  • When only 500 ⁇ g of acetyl fucoidan was added the proliferation rate of tumor cells was reduced to 80%.
  • moromi vinegar was added, it decreased to 90%.
  • the growth rate of the culture solution in which both were mixed decreased to 71%, and a significant synergistic effect was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

[Problème] Mettre en oeuvre une technique pouvant réduire le taux de prolifération de cellules cancéreuses, par administration d'un mélange comprenant du vinaigre moromi (patée de saké) moins cher.<i /> [[Solution] Le taux de prolifération des cellules cancéreuses est réduit à l'aide d'une matière comprenant un mélange de fucoidan dérivé d'algues marines et de vinaigre moromi.<i /> En particulier, en utilisant un mélange d'acétyl-fucoidan séparé de Cladosiphon okamuranus Tokida et de vinaigre moromi, le vinaigre moromi qui est moins cher peut remplacer l'acétyl-fucoidan et produire ainsi un effet de réduction de la quantité d'acétyl-fucoidan qui est onéreux à l'usage.<i /> <i /> <i /> Le vinaigre moromi ci-décrit est utilisé selon une quantité de 3 à 95%.<i /> Le fucoidan ci-décrit est dérivé d'une algue marine telle que Nemacystus decipiens, Undaria pinnatifida, Undaria pinnatifida sporophyll, Laminariaceae algae, Sargassum fusiforme, Sargassum horneri (Turner) C Agardh ou d'une algue marine de la famille Sargassaceae.<i /> <i /> <i /> <i /> <i /> <i />
PCT/JP2017/012202 2016-03-25 2017-03-25 PROCÉDÉ ANTICANCÉREUX OU MATÉRIAU ANTICANCÉREUX UTILISANT UN MÉLANGE DE FUCOIDAN ET DE VINAIGRE MOROMI<i /> WO2017164411A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018507462A JP6913266B2 (ja) 2016-03-25 2017-03-25 フコイダンともろみ酢とを混合した抗腫瘍方法又は物質

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016-062864 2016-03-25
JP2016062864 2016-03-25
JP2017051887 2017-03-16
JP2017-051887 2017-03-16

Publications (1)

Publication Number Publication Date
WO2017164411A1 true WO2017164411A1 (fr) 2017-09-28

Family

ID=59900412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/012202 WO2017164411A1 (fr) 2016-03-25 2017-03-25 PROCÉDÉ ANTICANCÉREUX OU MATÉRIAU ANTICANCÉREUX UTILISANT UN MÉLANGE DE FUCOIDAN ET DE VINAIGRE MOROMI<i />

Country Status (2)

Country Link
JP (2) JP6913266B2 (fr)
WO (1) WO2017164411A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138166A (ja) * 1993-09-24 1995-05-30 Yakult Honsha Co Ltd 抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤
JP2004352681A (ja) * 2003-05-30 2004-12-16 Denen Shuzo Kk がん細胞増殖抑制剤及びその製造方法
JP2007051081A (ja) * 2005-08-17 2007-03-01 Univ Of Ryukyus 抗腫瘍剤
JP2008022787A (ja) * 2006-07-21 2008-02-07 Hirokou Kk もずくエキス入り健康食品飲料
JP2009185009A (ja) * 2008-02-08 2009-08-20 Nissho Fine Life:Kk 消化管悪性腫瘍治療用経口医薬組成物
JP2012001704A (ja) * 2010-06-16 2012-01-05 Hamashoku:Kk モズク抽出の高分子フコイダンの低分子化法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3371124B2 (ja) * 1996-12-24 2003-01-27 正邦 田幸 養殖オキナワモズクを原料とするアセチルフコイダンおよ びそれの製造法
JP4571540B2 (ja) * 2005-06-10 2010-10-27 株式会社Ｍｇグローアップ フコイダンを含有する海藻類の処理方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138166A (ja) * 1993-09-24 1995-05-30 Yakult Honsha Co Ltd 抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤
JP2004352681A (ja) * 2003-05-30 2004-12-16 Denen Shuzo Kk がん細胞増殖抑制剤及びその製造方法
JP2007051081A (ja) * 2005-08-17 2007-03-01 Univ Of Ryukyus 抗腫瘍剤
JP2008022787A (ja) * 2006-07-21 2008-02-07 Hirokou Kk もずくエキス入り健康食品飲料
JP2009185009A (ja) * 2008-02-08 2009-08-20 Nissho Fine Life:Kk 消化管悪性腫瘍治療用経口医薬組成物
JP2012001704A (ja) * 2010-06-16 2012-01-05 Hamashoku:Kk モズク抽出の高分子フコイダンの低分子化法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUKAHORI S. ET AL.: "Fucoidan, a major component of brown seaweed, prohibits the growth of human cancer cell lines in vitro", MOL MED REP ., vol. 1, no. 4, 2008, pages 537 - 542, XP055601362, ISSN: 1791-2997 *
TAKEDA T. ET AL.: "Anti-tumor activity of fucoidan is mediated by nitric oxide released from macrophages", INT J ONCOL., vol. 40, 2012, pages 251 - 260, XP055601367, ISSN: 1019-6439 *

Also Published As

Publication number Publication date
JPWO2017164411A1 (ja) 2019-04-25
JP2021107450A (ja) 2021-07-29
JP6913266B2 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
Wang et al. Recent developments in Hericium erinaceus polysaccharides: extraction, purification, structural characteristics and biological activities
Shin et al. Polysaccharides from ginseng leaves inhibit tumor metastasis via macrophage and NK cell activation
Wang et al. Effect of monosaccharide composition and proportion on the bioactivity of polysaccharides: A review
Li et al. Isolation, structural characterization and bioactivities of polysaccharides from Laminaria japonica: A review
Ahmad et al. Therapeutic values and nutraceutical properties of shiitake mushroom (Lentinula edodes): A review
Ai et al. Polysaccharides from Spirulina platensis: Extraction methods, structural features and bioactivities diversity
Ermakova et al. Are multifunctional marine polysaccharides a myth or reality?
CN104664527A (zh) 一种具有防癌、抗癌、抗辐射、清除体内重金属的组合物
Yang et al. Recent developments in Moringa oleifera Lam. polysaccharides: A review of the relationship between extraction methods, structural characteristics and functional activities
Lee et al. Production, characterization, and functions of sulfated polysaccharides from zinc sulfate enriched cultivation of Antrodia cinnamomea
CN104619329A (zh) 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖-鼠李糖半乳糖醛酸酯组合物
Sanniyasi et al. In vitro anticancer potential of laminarin and fucoidan from Brown seaweeds
Li et al. Determining the potent immunostimulation potential arising from the heteropolysaccharide structure of a novel fucoidan, derived from Sargassum Zhangii
El-Sheekh et al. Medicinal and pharmaceutical applications of seaweeds
WO2017164411A1 (fr) PROCÉDÉ ANTICANCÉREUX OU MATÉRIAU ANTICANCÉREUX UTILISANT UN MÉLANGE DE FUCOIDAN ET DE VINAIGRE MOROMI&lt;i /&gt;
Jang et al. Exploring the health benefits and concerns of brown seaweed consumption: A comprehensive review of bioactive compounds in brown seaweed and its potential therapeutic effects
JP2008044912A (ja) ナガコンブ由来の抗腫瘍剤、ヒアルロニダーゼ阻害剤又はアトピー性皮膚炎治療剤
Liu et al. A systematic review on polysaccharides from Morinda officinalis How: Advances in the preparation, structural characterization and pharmacological activities
JP2014162726A (ja) 機能性組成物
Yang et al. Polysaccharides from marine biological resources and their anticancer activity on breast cancer
Senthil A comprehensive review to assess the potential, health benefits and complications of fucoidan for developing as functional ingredient and nutraceutical
Dhara et al. Apoptotic effect of sulfated galactofucan from marine macroalga Turbinaria ornata on hepatocellular and ductal carcinoma cells
Cheng et al. Preparation, structural characterization, bioactivities, and applications of Crataegus spp. polysaccharides: A review
JP2005068114A (ja) タモギタケ子実体組成物及びその製造方法、並びに免疫賦活剤、抗癌剤及び食品製剤
TW201914598A (zh) 混合褐藻醣膠與醪醋之抗腫瘤方法及物質

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17770451

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018507462

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 17770451

Country of ref document: EP

Kind code of ref document: A1